Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has reported E.P.S. of $0.10 for its first fiscal quarter (ending March 31) versus $-0.27 for the same period a year ago. This performance was $-0.18 short of the consensus estimate of $0.28. E.P.S. were $-0.01 for the latest four quarters through March 31 versus $-0.91 for the same period a year ago.
Recent Price Action
On 5/8/24, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock declined slightly by -0.7%, closing at $17.13. Trading volume in this decline was normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 2.5% during the last week.
Current PriceTarget Research Rating
ACAD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Acadia Pharmaceuticals has a poor Appreciation Score of 20 and a very low Power Rating of 10, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment